Compare AYTU & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | CNF |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 32.7M |
| IPO Year | 2015 | 2018 |
| Metric | AYTU | CNF |
|---|---|---|
| Price | $1.85 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 21.6K | 3.4K |
| Earning Date | 11-20-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.83 | $1.37 |
| 52 Week High | $3.07 | $6.49 |
| Indicator | AYTU | CNF |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 53.86 |
| Support Level | N/A | $1.74 |
| Resistance Level | $2.34 | $2.19 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 27.03 | 58.14 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.